HUP0201336A3 - The use of nmda antagonist compounds for producing medicaments useful for prophylaxis of dyskinesias - Google Patents

The use of nmda antagonist compounds for producing medicaments useful for prophylaxis of dyskinesias

Info

Publication number
HUP0201336A3
HUP0201336A3 HU0201336A HUP0201336A HUP0201336A3 HU P0201336 A3 HUP0201336 A3 HU P0201336A3 HU 0201336 A HU0201336 A HU 0201336A HU P0201336 A HUP0201336 A HU P0201336A HU P0201336 A3 HUP0201336 A3 HU P0201336A3
Authority
HU
Hungary
Prior art keywords
dyskinesias
prophylaxis
antagonist compounds
nmda antagonist
medicaments useful
Prior art date
Application number
HU0201336A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HU0201336D0 publication Critical patent/HU0201336D0/hu
Publication of HUP0201336A2 publication Critical patent/HUP0201336A2/hu
Publication of HUP0201336A3 publication Critical patent/HUP0201336A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0201336A 2001-04-23 2002-04-22 The use of nmda antagonist compounds for producing medicaments useful for prophylaxis of dyskinesias HUP0201336A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28587001P 2001-04-23 2001-04-23

Publications (3)

Publication Number Publication Date
HU0201336D0 HU0201336D0 (hu) 2002-06-29
HUP0201336A2 HUP0201336A2 (hu) 2004-04-28
HUP0201336A3 true HUP0201336A3 (en) 2004-07-28

Family

ID=23096048

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201336A HUP0201336A3 (en) 2001-04-23 2002-04-22 The use of nmda antagonist compounds for producing medicaments useful for prophylaxis of dyskinesias

Country Status (12)

Country Link
US (1) US20030004187A1 (hu)
EP (1) EP1254661A1 (hu)
JP (1) JP2002332246A (hu)
KR (1) KR20020082151A (hu)
CN (1) CN1382442A (hu)
AU (1) AU3439602A (hu)
CA (1) CA2381630A1 (hu)
HK (1) HK1048071A1 (hu)
HU (1) HUP0201336A3 (hu)
IL (1) IL149148A0 (hu)
PL (1) PL353582A1 (hu)
ZA (1) ZA200203180B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006031856A2 (en) 2004-09-13 2006-03-23 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
CA2684550A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. 渇望入力及び支援システム
KR101657420B1 (ko) * 2015-08-31 2016-10-14 고려공업검사 주식회사 열교환기 튜브 검사용 홀더
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134363A0 (en) * 1997-10-24 2001-04-30 Warner Lambert Co Method for treating disease-related or drug-induced dyskinesias
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda

Also Published As

Publication number Publication date
JP2002332246A (ja) 2002-11-22
ZA200203180B (en) 2003-10-22
HUP0201336A2 (hu) 2004-04-28
IL149148A0 (en) 2002-11-10
HK1048071A1 (zh) 2003-03-21
CN1382442A (zh) 2002-12-04
HU0201336D0 (hu) 2002-06-29
KR20020082151A (ko) 2002-10-30
AU3439602A (en) 2002-10-24
EP1254661A1 (en) 2002-11-06
CA2381630A1 (en) 2002-10-23
PL353582A1 (en) 2002-11-04
US20030004187A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
HK1099713A1 (en) Preparation for the prophylaxis of restenosis
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
HK1064035A1 (en) Pharmaceutical salts of 1-phenyl-3-dimethylamino-propane compounds
HUP0500851A2 (en) Process for the preparation of rosuvastatin
HUP0201336A3 (en) The use of nmda antagonist compounds for producing medicaments useful for prophylaxis of dyskinesias
AU2002341241A1 (en) Process for the preparation of fast dissolving dosage form
IL143106A0 (en) Process for the preparation of acetamide derivatives
HUP0401600A3 (en) Process for the preparation of 14-hydroxymorphine derivatives
PT1446107E (pt) Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
IL165137A0 (en) Process for the preparation of thioalkylamine derivatives
HUP0401599A3 (en) Extended release oral dosage form
PL373627A1 (en) Process for the preparation of melamine
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
AU2002337601A1 (en) Process for the preparation of simvastatin
AU2002359034A1 (en) Process for the preparation of simvastatin
IL162770A (en) Process for the preparation of 7??-methyl-estr-4-ene-3-one derivatives
IL164788A0 (en) Process for the preparation of 3-isochromanone
PL368905A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
SI1406888T1 (sl) Substituirane gama-laktonske spojine kot NMDA antagonisti
HUP0402343A3 (en) Substituted beta-aminoalcohols used as medicaments
TW557665U (en) Improved structure of tool for forming noodle
AU2002229479A1 (en) Preparation for the prophylaxis of restenosis
AU2002236397A1 (en) Machine for manufacturing of objects
SI1385850T1 (en) New process for the preparation of oxabispidines